H2020-JTI-IMI2-2018-16-single-stage
H2020-JTI-IMI2-2018-16-single-stage
- Programme
- H2020
- Funded projects (dataset)
- 5
- EU contribution (sum)
- €35,183,571
- Portal deadline
- —
Leading topic in historical projects: IMI2-2018-16-01
Start here
Suggested partners for this call
Who coordinated consortia under this call, plus a complementary slice (topic leaders, research partners, or frequent non-coordinators). For industry lists, CSV export, and consortium size — open Proposal partner finder.
Top coordinators
Organisations that coordinated the most funded projects under this call.
- Leiden University Medical Center2 coordinated
- BVS1 coordinated
- INSERM1 coordinated
- FOUNDATION LYGATURE1 coordinated
Organisations strong on this topic
Broader signal: frequent participants across funded projects tagged with the same topic codes as this call (not limited to coordinators).
- MEDIZINISCHE UNIVERSITAET WIEN3 topic projects
- FFUND BV2 topic projects
- JANSSEN PHARMACEUTICA NV2 topic projects
- UCPH2 topic projects
- MITOLOGICS2 topic projects
- SORBONNE UNIVERSITE2 topic projects
- UANTWERPEN2 topic projects
- ULEI2 topic projects
- CHRU BRETONNEAU TOURS1 topic projects
- CHU DE POITIERS1 topic projects
- GLAXOSMITHKLINE RESEARCH & DEVELOPMENT LIMITED1 topic projects
- INSERM TRANSFERT SA1 topic projects
Frequent collaborators
Pairs that often appear together in the same funded project under this call.
- ULEI · SORBONNE UNIVERSITE2 shared
NL ↔ FR
- MEDIZINISCHE UNIVERSITAET WIEN · FFUND BV2 shared
AT ↔ NL
- JANSSEN PHARMACEUTICA NV · UCPH2 shared
BE ↔ DK
- ULEI · MEDIZINISCHE UNIVERSITAET WIEN2 shared
NL ↔ AT
- 2 shared
- 2 shared
- 2 shared
- JANSSEN PHARMACEUTICA NV · MITOLOGICS2 shared
BE ↔ FR
- 2 shared
- JANSSEN PHARMACEUTICA NV · UANTWERPEN2 shared
BE ↔ BE
- 2 shared
- ULEI · MITOLOGICS2 shared
NL ↔ FR
- ULEI · Leiden University Medical Center2 shared
NL ↔ NL
- ULEI · UANTWERPEN2 shared
NL ↔ BE
- JANSSEN PHARMACEUTICA NV · ULEI2 shared
BE ↔ NL
- 2 shared
- JANSSEN PHARMACEUTICA NV · FFUND BV2 shared
BE ↔ NL
- MEDIZINISCHE UNIVERSITAET WIEN · INSERM2 shared
AT ↔ FR
Proposal partner finder
One page with suggested coordinators, strong and industry partners, topic leaders, typical consortium size, similar projects — plus CSV or print / PDF export for your shortlist.
Typical consortium pattern
Derived from historical funded projects linked to this CORDIS call in Grantibase.
- Avg. orgs / project
- 8.4
- Median orgs / project
- 9
- Min / max orgs
- 3 – 13
Country presence
Participant rows (an org can appear in multiple countries if data varies).
- France14
- Netherlands8
- Austria4
- Belgium4
- Germany3
- United Kingdom3
- Switzerland2
- Spain2
- Denmark2
Organization types
- university10 orgs · 19 rows
- sme6 orgs · 9 rows
- research_institute6 orgs · 7 rows
- company4 orgs · 6 rows
- other1 orgs · 1 rows
Topics in funded projects
- IMI2-2018-16-01IMI2-2018-16-01· 1 projects
- IMI2-2018-16-02IMI2-2018-16-02· 1 projects
- IMI2-2018-16-04IMI2-2018-16-04· 1 projects
- IMI2-2018-16-06IMI2-2018-16-06· 1 projects
- IMI2-2018-16-07IMI2-2018-16-07· 1 projects
Related funded projects
Largest EU contributions in this call — useful to see who already won funding on similar lines.
Open full project list in advanced search
| Project | Programme | EU contribution |
|---|---|---|
| GNA NOW NOVEL GRAM-NEGATIVE ANTIBIOTIC NOW | H2020 | €12,299,995 |
| TRIC-TB Boosting Ethionamide efficacy and lowering the dose with a small molecule transcriptional modulators, to overcoming MDR-TB infections and define a new place for Ethionamide in 1st-line TB treatments. | H2020 | €6,926,375 |
| RespiriTB Progress new assets (one pre-new molecular entity and one first-time-in-human start) for tuberculosis that act synergistically with bedaquiline, cytochrome bc or cytochrome bd inhibitors | H2020 | €6,840,000 |
| RespiriNTM Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline | H2020 | €5,687,984 |
| AB-DiRecT Antibiotic Distribution and Recovery in Tissue | H2020 | €3,429,217 |